KAO JOHN E 4
4 · Alignment Healthcare, Inc. · Filed Apr 13, 2026
Research Summary
AI-generated summary of this filing
Alignment Healthcare (ALHC) CEO John E. Kao Sells 298,000 Shares
What Happened
John E. Kao, CEO of Alignment Healthcare (ALHC), sold a total of 298,000 shares across three transactions in April 2026 for approximately $6.16 million in aggregate proceeds. The trades were reported on a Form 4 filed 2026-04-13 and consist of:
- 201,900 shares sold on 2026-04-10 — reported weighted-average price $20.58 — proceeds $4,155,243.
- 13,801 shares sold on 2026-04-10 — reported weighted-average price $21.38 — proceeds $295,045.
- 82,299 shares sold on 2026-04-13 — reported weighted-average price $20.80 — proceeds $1,711,655.
All transactions are recorded as sales (S) — routine dispositions rather than purchases.
Key Details
- Transaction dates: 2026-04-10 (two sales) and 2026-04-13 (one sale). Form 4 filed 2026-04-13 (appears timely).
- Aggregate shares sold: 298,000; aggregate proceeds: ~$6,161,943.
- Reported weighted-average prices and footnote price ranges:
- 201,900 @ $20.58 (per-share range reported 20.31–21.30).
- 13,801 @ $21.38 (per-share range reported 21.31–21.49).
- 82,299 @ $20.80 (per-share range reported 20.26–21.00).
The filer offers to provide exact per-price breakdowns on request (per filing footnotes).
- 10b5-1 plan: Filing notes a Rule 10b5-1 trading plan adopted 11/21/2025 (footnote). These plans set prearranged trades and are common for scheduled insider sales.
- Ownership after transaction: Not specified in the supplied summary of the filing.
- Trust holdings: Footnote indicates some securities are held by the JEK Trust (dated Feb 8, 2021), for which Mr. Kao is trustee.
Context
- These were straight sales (disposals), not purchases or option exercises. Sales under a 10b5-1 plan are typically pre-scheduled and do not by themselves indicate changed sentiment. Retail investors should view the activity as insider selling but note the 10b5-1 plan disclosure and weighted-average price ranges provided in the filing.
Insider Transaction Report
Form 4
KAO JOHN E
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
[F1][F2][F3]2026-04-10$20.58/sh−201,900$4,155,243→ 1,902,741 total(indirect: See Footnote) - Sale
Common Stock
[F1][F4][F3]2026-04-10$21.38/sh−13,801$295,045→ 1,888,940 total(indirect: See Footnote) - Sale
Common Stock
[F1][F5][F3]2026-04-13$20.80/sh−82,299$1,711,655→ 1,806,641 total(indirect: See Footnote)
Holdings
- 1,784,868
Common Stock
Footnotes (5)
- [F1]Date of Rule 10b5-1 plan adoption: 11/21/2025
- [F2]The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $20.31 to $21.30. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.
- [F3]Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.
- [F4]The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $21.31 to $21.49. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.
- [F5]The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $20.26 to $21.00. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.
Signature
/s/ Christopher J. Joyce, as Attorney-in-Fact, for John E. Kao|2026-04-13